Navigation Links
Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals
Date:6/3/2008

FRAZER, Pa., June 3 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that it and its wholly-owned subsidiary CIMA LABS INC. have filed a lawsuit in U.S. District Court in Delaware against Watson Pharmaceuticals, Inc. and its wholly-owned subsidiary, Watson Laboratories, Inc., for infringement of U.S. Patent Nos. 6,200,604 and 6,974,590, which cover methods of use for the Cephalon product FENTORA(R) (fentanyl buccal tablet) [C-II]. The 6,200,604 and 6,974,590 patents do not expire until 2019. FENTORA was approved by the U.S. Food and Drug Administration (FDA) in September 2006 for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

The lawsuit is based upon an Abbreviated New Drug Application (ANDA) filed by Watson seeking FDA approval for a generic equivalent of fentanyl buccal tablets to be sold in the United States. Watson alleges that the above two FENTORA patents are invalid, unenforceable and/or will not be infringed by Watson's manufacture, use or sale of the product described in its ANDA.

"We believe that the proposed Watson ANDA product infringes our patents," said Jerry Pappert, Executive Vice President and General Counsel. "The FENTORA patents were approved by the United States Patent and Trademark Office based on the results of extensive research by CIMA LABS. We continue to believe that our patent position for this product is strong and intend to vigorously defend our intellectual property."

The filing of this lawsuit is provided for by the Hatch-Waxman Act, a federal statute governing certain aspects of generic drug approvals. Under that statute, the filing of the lawsuit stays any FDA approval of the Watson ANDA until the earlier of a district court judgment in favor of Watson or 30 months from the company's April 2008 receipt of a Paragraph IV certification letter from Watson.

A
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... results before the Nasdaq market opens on Thursday, April ... and webcast to discuss its financial results and provide ... 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time). ... dialing 866-952-1906 (US) or 785-424-1825 (International) using the conference ...
(Date:4/23/2015)... LONDON , April 23, 2015 ... Medical Equipment   Report Details   ... reach a value of $101.3 billion in 2015 and will ... Strong growth in the healthcare sectors around the world and ... the key growth factors in the global healthcare packaging ...
(Date:4/23/2015)... 23, 2015 /PRNewswire/ - Crystal Research Associates, LLC announced ... ® (EIO) on Aeterna Zentaris Inc. (NASDAQ: ... on Crystal Research Associates, website at www.crystalra.com ... at www.aezsinc.com . Aeterna Zentaris ("Aeterna" ... company in oncology, endocrinology, and women,s health. With a ...
(Date:4/22/2015)... MN , April 22, 2015 /PRNewswire/ - BioAmber Inc. (NYSE and ... for the first quarter 2015 on Thursday, May 7, ... has scheduled a webcast and conference call for 4.30 ... Live audio of the conference call ... available to investors, members of the news media and ...
Breaking Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Healthcare Packaging Market Forecast 2015-2025 2Healthcare Packaging Market Forecast 2015-2025 3Healthcare Packaging Market Forecast 2015-2025 4Healthcare Packaging Market Forecast 2015-2025 5Healthcare Packaging Market Forecast 2015-2025 6Healthcare Packaging Market Forecast 2015-2025 7Healthcare Packaging Market Forecast 2015-2025 8Healthcare Packaging Market Forecast 2015-2025 9Healthcare Packaging Market Forecast 2015-2025 10Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 2Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 3BioAmber Announces Webcast of Fiscal First Quarter 2015 Financial Results 2
... whose MBA and undergraduate degree were minted at the ... Clear Software's North American operations, the company said on ... ,Cape Clear, headquartered in Massachusetts, provides "enterprise service bus" ... State of Wisconsin Department of Administraiton. , ,Though its ...
... are interested in bio and life science investments in ... Meanwhile the University of Wisconsin-Madison is introducing two new ... 30, 2005 Listen to this episode ... with companies in Madison ...
... Genzyme Corp. said on Wednesday it has agreed ... Wisconsin-Madison biotech spinoff, for $600 million in cash. , ,Bone ... more than $2 billion and almost 7,000 employees worldwide, plan ... companies recently reported healthy quarterly profits and revenues. Bone Care ...
Cached Biology Technology:Massachusetts firm to buy UW spinoff Bone Care for $600 million 2Massachusetts firm to buy UW spinoff Bone Care for $600 million 3
(Date:4/2/2015)... , April 2, 2015 ... tests DERMALOG by far outperforms the strongest competitors, ... maintaining high accuracy, the system is capable of ... the speed proves up to be ten times ... than its runner-up performance.      (Photo: ...
(Date:4/2/2015)... 2, 2015 Fingerprint Cards (FPC) ... FPC1025 from the distributor World Peace Industrial Group (WPI), ... 2015 although the major part of the shipments will ... used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK ...
(Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... Sweden and the University of Glasgow, Scotland, has identified a ... gastrointestinal bacteria. In a study published as a letter to ... suggesting that the human genome may play a role in ... human gastrointestinal tract collectively known as the gut microbiota. ...
... a classic example of evolutionary adaptation, with beaks that vary ... While living birds have a beak to manipulate their food, ... discovery shows some fossil birds evolved teeth adapted for specialized ... a new species of early bird, Sulcavis geeorum , ...
... by senior author Morris J. Birnbaum, MD, PhD, the ... Institute for Diabetes, Obesity, and Metabolism, Perelman School of ... metformin works in a different way than previously understood. ... liver hormone glucagon,s ability to generate an important signaling ...
Cached Biology News:International study suggests human genes influence gut microbial composition 2First fossil bird with teeth specialized for tough diet 2Most-used diabetes drug works in different way than previously thought 2
... of calcium binding proteins such as calmodulin and ... alpha and beta chain whereas S100B is composed ... also expressed in the antigen presenting cells such ... reticulum cells in the paracortex of lymph nodes. ...
Cytosol/Particulate Rapid Separation Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: 4C...
Request Info...
Polyclonal Antibody to CLAN...
Biology Products: